S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
Log in

Ardelyx Stock Forecast, Price & News

-0.05 (-0.73 %)
(As of 02/24/2021 12:00 AM ET)
Today's Range
Now: $6.83
50-Day Range
MA: $7.06
52-Week Range
Now: $6.83
Volume593,293 shs
Average Volume722,605 shs
Market Capitalization$616.39 million
P/E RatioN/A
Dividend YieldN/A
Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.
Ardelyx logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ARDX
Year FoundedN/A



Sales & Book Value

Annual Sales$5.28 million
Book Value$2.10 per share


Net Income$-94,940,000.00
Net Margins-1,063.74%


Market Cap$616.39 million
Next Earnings Date3/5/2021 (Estimated)


Overall MarketRank

1.89 out of 5 stars

Medical Sector

96th out of 1,958 stocks

Pharmaceutical Preparations Industry

38th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -
-0.05 (-0.73 %)
(As of 02/24/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARDX News and Ratings via Email

Sign-up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Ardelyx (NASDAQ:ARDX) Frequently Asked Questions

Is Ardelyx a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Ardelyx stock.
View analyst ratings for Ardelyx
or view top-rated stocks.

What stocks does MarketBeat like better than Ardelyx?

Wall Street analysts have given Ardelyx a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ardelyx wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Ardelyx's next earnings date?

Ardelyx is scheduled to release its next quarterly earnings announcement on Friday, March 5th 2021.
View our earnings forecast for Ardelyx

How were Ardelyx's earnings last quarter?

Ardelyx, Inc. (NASDAQ:ARDX) posted its quarterly earnings results on Tuesday, November, 10th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.28) by $0.08. The biopharmaceutical company had revenue of $2.71 million for the quarter, compared to analysts' expectations of $1.31 million. Ardelyx had a negative trailing twelve-month return on equity of 53.93% and a negative net margin of 1,063.74%.
View Ardelyx's earnings history

How has Ardelyx's stock been impacted by Coronavirus?

Ardelyx's stock was trading at $5.98 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ARDX shares have increased by 14.2% and is now trading at $6.83.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ARDX?

3 equities research analysts have issued twelve-month target prices for Ardelyx's shares. Their forecasts range from $14.00 to $14.00. On average, they anticipate Ardelyx's stock price to reach $14.00 in the next year. This suggests a possible upside of 105.0% from the stock's current price.
View analysts' price targets for Ardelyx
or view top-rated stocks among Wall Street analysts.

Who are Ardelyx's key executives?

Ardelyx's management team includes the following people:
  • Mr. Michael G. Raab, Pres, CEO & Director (Age 56, Pay $988k)
  • Ms. Elizabeth A. Grammer, Chief Legal & Admin. Officer and Sec. (Age 57, Pay $596k)
  • Mr. David Rosenbaum, Chief Devel. Officer (Age 60, Pay $617.25k)
  • Mr. Justin A. Renz CPA, MST, M.S.T., MBA, CFO & Chief Accounting Officer (Age 49)
  • Mr. Jeffrey W. Jacobs, Chief Scientific Officer (Age 58)
  • Ms. Kimia Keshtbod, Mang. of Corp. Communications & Investor Relations
  • Mr. Robert C. Blanks, Chief Regulatory Affairs & Quality Assurance Officer
  • Ms. Karen Harrigan, Sr. Director Market Devel.
  • Dan Pavicich, Sr. Director of Market Devel.
  • Ms. Susan Rodriguez, Chief Commercial Officer

Who are some of Ardelyx's key competitors?

What other stocks do shareholders of Ardelyx own?

What is Ardelyx's stock symbol?

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Who are Ardelyx's major shareholders?

Ardelyx's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.56%), Price T Rowe Associates Inc. MD (2.77%), Pekin Hardy Strauss Inc. (1.75%), Candriam Luxembourg S.C.A. (1.52%), Ikarian Capital LLC (1.28%) and Northern Trust Corp (0.95%). Company insiders that own Ardelyx stock include David M Mott, David P Rosenbaum, Elizabeth A Grammer, Forest Baskett, Jeffrey W Jacobs, Justin A Renz, Mark Kaufmann, Michael Raab, Robert Blanks, Scott D Sandell and Susan Rodriguez.
View institutional ownership trends for Ardelyx

Which institutional investors are selling Ardelyx stock?

ARDX stock was sold by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Renaissance Technologies LLC, Pekin Hardy Strauss Inc., Wells Fargo & Company MN, Price T Rowe Associates Inc. MD, State of Wisconsin Investment Board, Principal Financial Group Inc., and Northern Trust Corp. Company insiders that have sold Ardelyx company stock in the last year include Elizabeth A Grammer, Forest Baskett, Jeffrey W Jacobs, Justin A Renz, Michael Raab, Robert Blanks, Scott D Sandell, and Susan Rodriguez.
View insider buying and selling activity for Ardelyx
or view top insider-selling stocks.

Which institutional investors are buying Ardelyx stock?

ARDX stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Janus Henderson Group PLC, Silverarc Capital Management LLC, Russell Investments Group Ltd., BlackRock Inc., Bailard Inc., ExodusPoint Capital Management LP, and Nuveen Asset Management LLC.
View insider buying and selling activity for Ardelyx
or or view top insider-buying stocks.

How do I buy shares of Ardelyx?

Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ardelyx's stock price today?

One share of ARDX stock can currently be purchased for approximately $6.83.

How much money does Ardelyx make?

Ardelyx has a market capitalization of $616.39 million and generates $5.28 million in revenue each year. The biopharmaceutical company earns $-94,940,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis.

How many employees does Ardelyx have?

Ardelyx employs 88 workers across the globe.

What is Ardelyx's official website?

The official website for Ardelyx is www.ardelyx.com.

Where are Ardelyx's headquarters?

Ardelyx is headquartered at 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555.

How can I contact Ardelyx?

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected]

This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.